Cagrilintide

What it is

Cagrilintide is built from the structure of amylin, a hormone the pancreas releases alongside insulin that helps signal fullness after eating and helps regulate how quickly sugar enters the bloodstream. Researchers attached a fatty-acid side chain to the amylin-based sequence so that it binds loosely to a blood protein called albumin, which slows how quickly the body clears it and allows once-weekly injections instead of injections several times a day.

Cagrilintide activates both amylin receptors and a related target called the calcitonin receptor. Much of the recent research studies it paired with semaglutide, a separate appetite-regulating hormone-based drug, under the combined name CagriSema, on the idea that the two work through different pathways and might add to each other's effect on appetite and body weight [1][2].

How it is studied

Cagrilintide has gone through large, randomized, placebo- and active-controlled Phase 3 trials in thousands of adults with obesity or type 2 diabetes, given as a once-weekly injection under the skin for 68 weeks, usually alongside semaglutide as the CagriSema combination [1][2]. A separate smaller human study specifically tested the compound's effect on heart electrical activity, using a standard cardiac-safety trial design at doses higher than the ones used for weight management [3].

What studies report

• In a 68-week trial of over 3,400 adults with obesity, the CagriSema combination was linked to average weight loss of about 23 percent, compared with roughly 2 percent for placebo. [1]
• In a 68-week trial of adults with obesity and type 2 diabetes, CagriSema was linked to about 16 percent average weight loss along with meaningful improvement in blood sugar control for most participants. [2]
• A dedicated heart-safety study found no meaningful lengthening of the heart's electrical recovery time, even at doses higher than those used for weight management. [3]

What is not known

As of these trial reports, cagrilintide had not yet received regulatory approval on its own or as the CagriSema combination, so its long-term safety and effectiveness beyond the 68-week trial window has not been established. Antibodies against the drug developed in a substantial share of trial participants; the trials reported this did not appear to reduce how well the drug worked, but longer-term consequences of that immune response have not been studied.

Reported adverse findings

• The most commonly reported side effects across the large trials were digestive symptoms such as nausea, vomiting, and diarrhea, concentrated in the first weeks of treatment, and only about 57 percent of participants in one trial reached and stayed on the highest planned amount. [1]

Regulatory status

Cagrilintide, alone or as the CagriSema combination, had not received FDA approval at the time of the cited trial reports, with regulatory review described as ongoing. Health Canada and other major regulators have likewise not granted it approval for any use.